Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S

Bridge Biotherapeutics Announces Initiation Of Phase 1/2 Clinical Trial Of Bbt 176 In Egfr Mutant Nsclc With C797s

Facebook Comments

Leave a Reply

CommentLuv badge